Enersense will build three 110kV power grid substations in Finland.
Equity analyst interviews Elanders' CEO Magnus Nilsson and CFO Andreas Wikner after their Q4.
Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and ...
A SEK 20m to SEK 35m financing based with the financial partner Formue Nord Fokus A/S eases the fina...
Vast majority of inventory normalisation... ...likely to be completed in the coming 6-9 months '23e-...
Having already achieved proof-of-performance for its proprietary digital technique for detection of ...
Consti’s Q4 figures missed our estimates mainly due to lower volumes than expected.
Redeye updates its estimates and valuation following Lifco’s Q4 2023 report.
Redeye views the bounce back for Tagmaster after a weak Q3 report as encouraging.
Ferronordic will report its Q4 2023 results on 22 February.
Redeye takes a neutral view on Addnode following a solid Q4 report.
5.2% organic sales growth, improving margins EBITDA up 1.
Redeye continue to see an exciting case in Nanologica despite the Q4 report falling short of sales a...
Redeye shares its preview of Sedana Medical’s Q4 2023e results, due February 15.
Q4 EBIT -100mkr Q4 påverkades kraftigt negativt av låga massapriser, höga råvarupriser och underhåll...
Market-leading white-label software provider for takeaway restaurants 13% ARR CAGR and 11pp EBITDA m...
Redeye gives its initial take on Kontigo Care’s Q4 2023 report, which came in slightly softer than w...
DT’s Q4 results topped estimates as costs remained under control while SBU continued to drive growth...
Consti's net sales in Q4 amounted to EUR 86.1m, below our estimates (Evli est.
SRV’s current low risk backlog will support it through the tougher market with hopes for higher marg...
